ethyl 3-chlorosulfonylpyrazole-4-carboxylate | 115703-22-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 3-chlorosulfonylpyrazole-4-carboxylate
• 英文别名: ethyl 5-(chlorosulfonyl)-1H-pyrazole-4-carboxylate；ethyl 5-chlorosulfonyl-1H-pyrazole-4-carboxylate
• CAS: 115703-22-5
• 化学式: C₆H₇ClN₂O₄S
• mdl: MFCD08691284
• 分子量: 238.652
• InChiKey: LEQLXEAEARQQJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  97.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 3-chlorosulfonylpyrazole-4-carboxylate 在 一水合肼 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以75%的产率得到3-hydrazinosulfonyl-1H-pyrazole-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  Fused 3-Hydroxy-3-trifluoromethylpyrazoles Inhibit Mutant Huntingtin Toxicity

  摘要：

  Here, we describe the selection and optimization of a chemical series active in both a full-length and a fragment-based Huntington's disease (HD) assay. Twenty-four thousand small molecules were screened in a phenotypic HD assay, identifying a series of compounds bearing a 3-hydroxy-3-trifluoromethylpyrazole moiety as able to revert the toxicity induced by full-length mutant Htt by up to 50%. A chemical exploration around the series led to the identification of compound 4f, which demonstrated to be active in a Htt171-82Qrat primary striatal neuron assay and a PC12-Exon-1 based assay. This compound was selected for testing in R6/2 mice, in which it was well-tolerated and showed a positive effect on body weight and a positive trend in preventing ventricular volume enlargment. These studies provide strong rationale for further testing the potential benefits of 3-hydroxy-3-trifluoromethylpyrazoles in treating HD.

  DOI：

  10.1021/ml400251g
• 作为产物：
  描述：

  2-氰基-3-乙氧基丙烯酸乙酯 在 盐酸 、 一水合肼 、 sodium nitrite 作用下， 以 乙醇 、 水 为溶剂， 反应 5.0h， 生成 ethyl 3-chlorosulfonylpyrazole-4-carboxylate
  参考文献：
  名称：

  [EN] MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS
  [FR] DÉRIVÉS DE SULFONYLAMIDE MACROCYCLIQUES UTILES EN TANT QU'INHIBITEURS DE NLRP3

  摘要：

  本发明涉及大环化合物，如大环磺酰胺。本发明还涉及相关的盐、溶剂化合物、前药和药物组合物，以及利用这些化合物在治疗和预防医学疾病和疾病中的应用，尤其是通过NLRP3抑制。

  公开号：

  WO2021032588A1

文献信息

• [EN] MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS<br/>[FR] DÉRIVÉS DE SULFONYLAMIDE MACROCYCLIQUES UTILES EN TANT QU'INHIBITEURS DE NLRP3
  申请人：INFLAZOME LTD

  公开号：WO2021032588A1

  公开（公告）日：2021-02-25

  The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl amides. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

  本发明涉及大环化合物，如大环磺酰胺。本发明还涉及相关的盐、溶剂化合物、前药和药物组合物，以及利用这些化合物在治疗和预防医学疾病和疾病中的应用，尤其是通过NLRP3抑制。
• Synthesis of 1<i>H</i>- and 2<i>H</i>-pyrazolo[3,4-<i>c</i>][2,1]benzothiazepines
  作者：Juan A. Diaz、Salvador Vega

  DOI：10.1002/jhet.5570310117

  日期：1994.1

  Starting from ethyl chlorosulfonylpyrazole-4-carboxylates we have carried out the synthesis of ketones 3 and 4 which are the first two structures of the novel 1H- and 2H-pyrazolo[3,4-c][2,1]benzothiazepine ring systems.

  从氯磺酰基吡唑-4-羧酸乙酯开始，我们进行了酮3和4的合成，它们是新颖的1 H-和2 H-吡唑并[3,4- c ] [2,1]苯并硫氮杂ring环的前两个结构系统。
• Synthesis and Anti-inflammatory Evaluation of New Sulfamoylheterocarboxylic Derivatives
  作者：Juan A. Díaz、M. Esther Morante、Salvador Vega、Victoriano Darias、Susana Abdala、Laura Delgado、Beatriz de las Heras、Angel Villar、José María Vivas

  DOI：10.1002/ardp.19963290503

  日期：——

  A series of new sulfamoylthiophene and sulfamoylpyrazole carboxylic acid derivatives was synthesized. Some of these compounds show interesting analgesic properties and significant nonsteroidal anti‐inflammatory activities in several models of inflammation.

  合成了一系列新的氨磺酰噻吩和氨磺酰吡唑羧酸衍生物。其中一些化合物在几种炎症模型中显示出有趣的镇痛特性和显着的非甾体抗炎活性。
• Vega; Diaz, Pharmazie, 1992, vol. 47, # 10, p. 765 - 767
  作者：Vega、Diaz

  DOI：——

  日期：——
• MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS
  申请人：Inflazome Limited

  公开号：EP4013762A1

  公开（公告）日：2022-06-22